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There has not been a new reversible contraceptive for men since the development of the condom,
centuries ago. Matzuk et al. describe a new molecular approach using administration of a small
molecule to directly and reversibly inhibit spermatogenesis in mice by blocking the function of
a testicular bromodomain without apparent adverse effect on the organism or offspring.Contraceptives have been in the news
a lot lately. The Obama administration
has mandated financial coverage for
contraceptives by many federally funded
health plans, generating predictable sup-
port from women’s groups and others
and resistance from some religious
leaders. The Gates Foundation, particu-
larly Melinda Gates, has pledged new,
extensive financial support for contracep-
tives for women, with the highly laudable
goal of preventing maternal death and
disease due to unwanted pregnancies
(Goldberg, 2012). Various governments,
led by Great Britain, have also pledged
new financial support to the same goal.
In these discussions, there has been
little mention of contraceptives for men,
although nearly one-third of contracep-
tion in the United States is accomplished
using the male-directed methods of
condoms or vasectomy (Piccinino and
Mosher, 1998). Studies directed at
new reversible contraceptives for men
have predominantly employed hormonal
approaches, somewhat analogous to
those used in women and designed to
suppress the pituitary hormones required
for gamete production. In this issue,
Matzuk et al. (2012) report an exciting
new approach to male contraception
using systemic administration of a small
molecule (JQ1) that inhibits the function
of the testis-specific bromodomain
(BRDT) that is required for chromatin re-
modeling, which, in turn, is necessary for
germ cell maturation.
In contrast to the variety of contracep-
tives available for women, the contracep-
tives available for men consist only of
condoms, vasectomy, and withdrawal ofthe penis from the vagina prior to ejacula-
tion during sexual intercourse. Condoms,
though very useful in the prevention of
sexually transmitted infections, have a
relatively high failure rate as contracep-
tives and have problems with accept-
ability and compliance. Vasectomy is
a very effective and safe technique but
must usually be considered as a perma-
nent contraceptive (expensive microsur-
gery with uncertain return of fertility is
occasionally employed). Withdrawal has
an uncertain efficacy rate and problems
with acceptability. It is quite surprising to
most people to learn that, despite the
problems with existing techniques, nearly
one-third of couples choose a male-
directed contraceptive method, demon-
strating that men will use contraceptives
if they are available.
Recent clinical research in male con-
traception has generally focused on hor-
monal approaches (Page et al., 2008).
These use androgens, often with pro-
gestins, to suppress the production of
gonadotropins from the pituitary, thereby
dramatically inhibiting production of
spermatozoa. Using such approaches in
normal, fertile couples has demonstrated
effective contraception with failure rates
much lower than the condom. However,
such approaches have not yet found
favor with the pharmaceutical industry
and have not come into clinical use.
Biological challenges facing investiga-
tors working on male contraceptives
include: (1) the amazing numbers of
spermatozoa produced by normal men,
1,000 per heart beat, (2) the difficulty of
fully suppressing these millions of sper-
matozoa produced daily compared toCell 15the relative ease of preventing the
production of one ovum per month in the
female, (3) concern that affecting pro-
duction of cells in the germline could alter
the genetics of offspring, and (4) the fact
that much of spermatogenesis occurs
‘‘behind’’ the blood-testis barrier (analo-
gous to the blood-brain barrier), which
prevents access of many molecules,
especially larger ones, to most of the
cells in the seminiferous tubules. These
challenges are in addition to the usual
issues faced in the development of
pharmaceuticals, such as unexpected
adverse effects, large financial expendi-
tures, and regulatory hurdles.
Despite these daunting challenges,
James Bradner and colleagues (Matzuk
et al., 2012) have entered the fray with
an impressive set of studies that convinc-
ingly demonstrate the ability of a new,
small molecule (JQ1) to cross the blood-
testis barrier and dramatically inhibit the
production of spermatozoa to the point
of infertility in experimental animals.
Furthermore, in contrast to many com-
pounds studied earlier, when administra-
tion of JQ1 is stopped, spermatogenesis
fully recovers, the animals suffer no
obvious ill effects on the testes or other
tissues, and the offspring of the treated
males seem normal. And all of this is
done without affecting the hormonal
balance of the recipient animals.
As Matzuk et al. describe, their work
was, in part, inspired by earlier work on
BRDT from the laboratory of Debra
Wolgemuth, who has contributed greatly
to our understanding of testicular biology.
Shang et al. (2007) demonstrated that
selective deletion of the amino terminal0, August 17, 2012 ª2012 Elsevier Inc. 667
region of BRDT, which results in loss of
the first two bromodomains (BrdtDBD1),
led to sterility in mice. BRDT is a protein
associated with chromatin in male germ
cells, and in BrdtDBD1 mice, there is
abnormal spermiogenesis (Berkovits and
Wolgemuth, 2011). Filippakopoulos et al.
(2010) demonstrated the possibility that
small molecules, including JQ1, could
target bromodomains, leading to the
work reported in this issue. Matzuk et al.
(2012) provide structural studies of JQ1
bound to BRDT(1), resulting in occlusion
of the acetyl-lysine recognition site
required for action, and also physiological
studies in vivo, demonstrating inhibition
of spermatogenesis and a reversible con-
traceptive effect without affecting blood
testosterone or gonadotropin levels or
mating behavior. The fact that gonado-
tropin levels, particularly follicle-stimu-
lating hormone (FSH), were normal is
consistent with the postulated site of
action in the germ cells of the seminif-
erous epithelium rather than the Sertoli
cells, which are often affected by agents
targeted at the testis and would likely
have caused decreased inhibin levels,
allowing an increase in blood FSH levels.
Another line of work also shows consid-
erable promise for a new orally available
contraceptive agent directed at the
testes. It is well established that vitamin
A is required for normal spermatogenesis
through the production of retinoic acid in
the testes. It has been known for decades668 Cell 150, August 17, 2012 ª2012 Elseviethat bisdichloroacetyldiamines (BDADs)
inhibit spermatogenesis. Recently, Amory
et al. (2011) have presented good
evidence that BDADs exert their inhibi-
tion of spermatogenesis by blocking
the testicular aldehyde dehydrogenase
necessary for converting retinol to retinoic
acid. Wolgemuth has also reported
recently that an inhibitor of retinoic acid
receptors will reversibly inhibit spermato-
genesis (Chung et al., 2011). The under-
standing of this control mechanism
provides another promising nonhormonal
target for male contraceptive develop-
ment, although both types of agents
have many challenges ahead, particularly
establishing lack of adverse effects of the
agents used.
Melinda Gates is doing a very admi-
rable job of highlighting the thousands of
women dying of maternal complications
of unwanted pregnancies around the
world and of providing resources to help
prevent these outcomes. In addition,
there are thousands of women dying of
abortion in unsafe circumstances, also
due to unwanted pregnancies. Men
should be given additional opportunities
to participate in safe contraception, both
to allow them more control over their
own fertility and to ease the health burden
of unwanted pregnancies and contracep-
tion incurred by women. The application
of new contraceptive techniques should
also help with preventing the dramatic
numbers of children resulting fromr Inc.unwanted pregnancies globally, particu-
larly in Sub-Saharan Africa and South
Asia, where fertility rates are still very
high. If as successful as hoped, the new
advances in contraception could become
textbook examples of the ability of trans-
lational science to truly better the human
condition worldwide.REFERENCES
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